Zoetis Inc (ZTS.N)

ZTS.N on New York Stock Exchange

46.46USD
5 Mar 2015
Change (% chg)

$0.23 (+0.50%)
Prev Close
$46.23
Open
$46.69
Day's High
$46.83
Day's Low
$45.99
Volume
482,585
Avg. Vol
848,568
52-wk High
$47.61
52-wk Low
$28.14

ZTS.N

Chart for ZTS.N

About

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The primary livestock species are cattle (both beef and dairy), swine, poultry, sheep and fish, and the primary companion animal species are dogs,... (more)

Overall

Beta: --
Market Cap(Mil.): $23,151.42
Shares Outstanding(Mil.): 500.79
Dividend: 0.08
Yield (%): 0.72

Financials

  ZTS.N Industry Sector
P/E (TTM): 39.81 39.99 40.54
EPS (TTM): 1.16 -- --
ROI: 11.06 16.87 16.20
ROE: 51.80 17.39 17.17
Search Stocks

Hedge fund Pershing Square wins board seat at Zoetis

BOSTON - Hedge fund Pershing Square Capital Management won one seat on the board of directors of animal health company Zoetis Inc and agreed with management to select a second "mutually agreeable" director, Zoetis said on Wednesday.

05 Feb 2015

Hedge fund Pershing Square wins board seat at Zoetis

BOSTON, Feb 4 - Hedge fund Pershing Square Capital Management won one seat on the board of directors of animal health company Zoetis Inc and agreed with management to select a second "mutually agreeable" director, Zoetis said on Wednesday.

04 Feb 2015

Deals of the day- Mergers and acquisitions

Jan 29 - The following bids, mergers, acquisitions and disposals were reported by 1115 GMT on Thursday:

30 Jan 2015

CORRECTED-Connections between drug makers and educators abound

(Corrects second paragraph to say "scholarships funded by Merck, Zoetis, Cargill and others this year.")

23 Dec 2014

Powerful antibiotic for cows often misused by farmers

NEW YORK/ATLANTA - It is one of the most potent antibiotics used by U.S. cattle and dairy farmers, the key component in the top-selling drug line of Zoetis, the world’s largest animal health company.

04 Dec 2014

BRIEF-Jinhe Biotechnology in sales contract with Zoetis

* Says signs sales contract for at least 301.05 million yuan(49.06 million US dollar) per year in 2015-2019 with Zoetis Inc's units in Belgium and Singapore

25 Nov 2014

Bayer explores possible sale of diabetes device unit: Bloomberg

- Germany-based drugmaker Bayer AG is considering the sale of its diabetes device business, Bloomberg reported, citing sources.

25 Nov 2014

Bayer explores possible sale of diabetes device unit -Bloomberg

Nov 24 - Germany-based drugmaker Bayer AG is considering the sale of its diabetes device business, Bloomberg reported, citing sources.

25 Nov 2014

Losing Allergan deals blow to Valeant reputation

WINNIPEG/NEW YORK - The failure of Valeant Pharmaceuticals International Inc to buy Allergan Inc leaves it with nothing to show for a seven-month, bruising pursuit.

17 Nov 2014

Losing Allergan deals blow to Valeant reputation

WINNIPEG/NEW YORK Nov 17 - The failure of Valeant Pharmaceuticals International Inc to buy Allergan Inc leaves it with nothing to show for a seven-month, bruising pursuit.

17 Nov 2014

Competitors

  Price Chg
Novartis AG (NOVN.VX) CHF96.30 +1.10
Merck & Co., Inc. (MRK.N) $57.98 +0.10
Bayer AG (BAYGn.DE) €133.35 +0.85
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €87.84 +0.39
Eli Lilly and Co (LLY.N) $70.59 -0.06

Earnings vs. Estimates

Search Stocks